Robotic systems are poised to advance thoracic surgery like never before. Many of these next steps are happening at Temple.
Pioneered in the 1980s and used commercially since the 1990s, robotic surgery is now standard of care in specialties such as urology, gynecology and colorectal surgery. Adoption has been slower in the high-acuity field of thoracic surgery—yet robotic surgery is simpler to learn than other minimally invasive techniques, and, once a surgeon develops expertise, they can operate with greater precision and several key advantages. Continue Reading >
Temple is taking part in a clinical trial to evaluate a new device that may improve outcomes among patients with respiratory failure by reducing — or eliminating — the time they are subjected to invasive mechanical ventilation. Some patients with acute COPD exacerbation experience hypercapnic respiratory failure. Continue Reading >
A 53-year-old African American man with a known history of advanced pulmonary sarcoidosis, obstructive sleep apnea on CPAP and mild pulmonary hypertension, was initially evaluated for possible lung transplant. He then presented with a first episode of spontaneous left pneumothorax requiring thoracostomy tube placement. Continue Reading >
A clinical trial at the Temple Lung Center aims to treat chronic bronchitis in a completely new way, by targeting the lung cells at the root of the condition. In January, Temple performed the region’s first bronchoscopic procedure using Gala Therapeutics’ “RheOx™” device to ablate cells in the lung lining that overproduce mucus in a patient with chronic bronchitis. Continue Reading >
Studies at the Lewis Katz School of Medicine and the Temple Lung Center are examining potential treatments for chronic obstructive pulmonary disease (COPD) based on the naturally occurring polyphenol quercetin. COPD is the third-leading cause of death in the United States; at present, there is no cure. Continue Reading >
The December 2018 announcement of FDA approval on the Olympus Spiration® Valve System (SVS) means patients now have a second option for minimally invasive endobronchial valve treatment for severe emphysema. The Spiration® Valve System was granted priority review status and approval under the FDA’s breakthrough medical devices designation. Continue Reading >